Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
The presence of blood in the urine is the medical condition termed as hematuria. Kidney stones, urinary tract infection (UTI), and inherited diseases are some of the major causes of hematuria. This disease is a serious issue as normal urine does not contain red blood cells (RBC). Reason of presence of blood in the urine include infection in the bladder, kidney, or prostate, vigorous exercise, viral illness, such as hepatitis a virus that causes liver disease and inflammation of the liver. In more serious cases the reason that causes hematuria include More serious reasons people may have hematuria include bladder or kidney cancer, inflammation of the kidney, urethra, bladder, or prostate which is a walnut-shaped gland in men that surrounds the urethra and helps make semen, blood-clotting disorders such as hemophilia. Major factors such as rising frequency rate in numerous types of hematuria and increasing awareness boost the market rate.
The hematuria treatment market is majorly driven by increase in frequency rate in numerous types of hematuria and increasing awareness regarding the disease and its treatment market rate. Moreover technological advancement such as drug delivery systems and focus on delivering better quality of life are some of the factors contributing to the growth of the market. However, increase in healthcare expenditure, and increasing awareness is expected to fuel the growth of the market in the forecast period. Also the growth of hematuria treatment market enhanced by the growing cases of hematuria treatment which create an opportunity for the pharma companies to introduce novel therapy and promising pipeline drug are some of the factors contributing to the growth of this market.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the global hematuria treatment market. In addition, complete analysis of changes on the global hematuria treatment market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on global economies, international trade, business investments, GDP and marketing strategies of key players present in the market. Due to the emergence of COVID-19 the patients infected with the corona virus disease faced severe issue and acute kidney infection due to the heavy dosage of medicine required to treat the corona virus disease. There was a positive impact of the pandemic on the hematuria treatment market.
The hematuria treatment market comprises of different market segment like type, indication, treatment, end user and geography.
The hematuria treatment is available in market according different type including macroscopic hematuria, microscopic hematuria, idiopathic hematuria, jogger’s hematuria. The microscopic hematuria segment leads the market and accounted for the major market share in the hematuria treatment market. The segment is expected to maintain its dominance in the forecast period due to the increase in number of patients suffering from microscopic hematuria. Microscopic hematuria has red blood cells in the urine. These blood cells are so small and are unable to see the blood in the urine.
The hematuria treatment market has different indication like urinary tract infections, kidney stones, urethritis, blood cancer, bladder stones, prostate cancer, cystitis, trauma, vigorous exercise, polycystic kidney disease, endometriosis, menstruation. The urinary tract infections segment is expected to hold the largest market share. Hematuria can be caused by an infection in any part of the urinary tract most commonly the bladder or the kidney. Symptoms of the infection depends upon the site of infection, but can include intense pain on one side of the mid-back, shaking chills, fever, nausea and vomiting, pain above the pubic or bladder region. Also the hematuria treatment market for urethritis segment is also expected to register the fastest growing segment in the forecast period.
The hematuria treatment market includes different treatments such as drugs, therapies. The drugs segment held the largest share of the market. To treat the infection antibiotics and medications help to increase the amount of urine excreted from the body, medications to control high blood pressure and dietary changes to reduce the work of the kidneys. Adrenochrome monosemicarbazone is a drug that is in the treatment of hematuria also having shock wave therapy to break up bladder or kidney stones. In some cases, no treatment is necessary. Despite various treatment options, management of intractable hematuria in patients with inoperable bladder cancer remains a challenge.
The hematuria treatment market finds its major end user in hospitals, clinics, ambulatory surgical centers, others. The hospital segment led the market as the prevalence of hematuria is higher in the patients who are at high risk of developing urologic diseases. The diagnosis and the treatment of hematuria depend upon the medical history and a thorough physical examination. If the hematuria is caused due to the urinary tract infections medications such as antibiotics and therapy such as shock wave therapy for treating the bladder or kidney stones and medications to shrink enlarged prostate gland are boosting the growth of the hospital segment in the forecast period.
The global hematuria treatment market is studied for the following region North America, Europe, Asia-Pacific and Rest of the world (RoW). North America dominated the market and accounts to hold the largest market share in the forecast period. Due to the early adoption of advanced medical technologies and continuous development by companies operating in the hematuria treatment market is propelling the growth of the market in the region. Also Europe accounts to be the second largest market owing to the increase in the prevalence of urinary tract infections associated with women. The government funding and support from the healthcare sector coupled with increasing research and development contributes to the growth of the market. The Asia-Pacific region is also expected to experience growth in the forecast period owning to growing demand for advanced technology, optimal treatment facilities, increasing government initiatives, better adoption rate, and rising healthcare expenditure.
The key players in hematuria treatment market are AstraZeneca, Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., GlaxoSmithKline plc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim International GmbH and The Medicines Company among others.
September 2021: AstraZeneca collaborated with VaxEquity for the discovery, development, and commercialization of the proprietary self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London.
September 2021: Merck announced its definitive agreement to acquire Acceleron. Following the purchase of shares in the tender offer, Acceleron will become a subsidiary of Merck.
August 2021: Pfizer Inc. and Trillium Therapeutics Inc. entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical stage immuno-oncology company developing innovative therapies for anticancer treatments.
June 2021: Eisai Co., Ltd. and Bristol-Myers Squibb Company entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC).
July 2021: GlaxoSmithKline plc. and Alector, announced a strategic global collaboration for the development and commercialization of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels.
The report analyses the hematuria treatment market based on by type, indication, treatment, end user and geography. The hematuria treatment is available in market according different type including macroscopic hematuria, microscopic hematuria, idiopathic hematuria, jogger’s hematuria. The microscopic hematuria segment leads the market and accounted for the major market share in the hematuria treatment market. The hematuria treatment market has different indication like urinary tract infections, kidney stones, urethritis, blood cancer, bladder stones, prostate cancer, cystitis, trauma, vigorous exercise, polycystic kidney disease, endometriosis, menstruation. The hematuria treatment market includes different treatments such as drugs, therapies. The drugs segment held the largest share of the market. To treat the infection antibiotics and medications help to increase the amount of urine excreted from the body, medications to control high blood pressure and dietary changes to reduce the work of the kidneys. The hematuria treatment market finds its major end user in hospitals, clinics, ambulatory surgical centers, others. The hospital segment led the market as the prevalence of hematuria is higher in the patients who are at high risk of developing urologic diseases. The hematuria treatment market finds its major end user in hospitals, clinics, ambulatory surgical centers, others. The hospital segment led the market as the prevalence of hematuria is higher in the patients who are at high risk of developing urologic diseases. The global hematuria treatment market is studied for the following region North America, Europe, Asia-Pacific and Rest of the world (RoW).
Why to buy this report
